Sarepta stock reaction overdone, says Barclays

Barclays reiterated an Overweight rating and $209 price target on Sarepta (SRPT) after the company reported a patient death post treatment of Elevidys due to acute liver failure. While one patient death was somewhat surprising and unfortunate, the liver toxicity was known, and the cause could be a multi-factor, particularly patient condition, the analyst tells investors in a research note. The firm added that initial feedback suggested limited impact on Elevidys patient use, and believes the stock reaction is overdone.